美團點評-W(03690.HK)擬發行20億美元優先票據
格隆匯 10 月 22日丨美團點評-W(03690.HK)發佈公告,2020年10月21日(紐約時間),公司及初始買家就發行7.50億美元於2025年到期的2.125%優先票據及12.5億美元於2030年到期的3.05%優先票據訂立購買協議。
扣除包銷佣金及若干估計發售開支後,票據發行的所得款項淨額將約為19.87億美元。公司擬將票據發行所得款項淨額用於一般企業用途及進行再融資。若發生意料之外的事件或業務狀況轉變,公司可按不同於上文所述的方式動用票據發行的所得款項淨額,惟須符合適用的中國內地法律及法規。
公司將就批准票據以僅向專業投資者發債方式上市及買賣向聯交所提出申請。公司已收到聯交所發出的有關票據上市的資格確認書。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.